Literature DB >> 19347351

Haptoglobin genotype and endothelial function in diabetes mellitus: a pilot study.

Lior Dayan1, Andrew P Levy, Shany Blum, Rachel Miller-Lotan, Uzi Melman, Jonia Alshiek, Giris Jacob.   

Abstract

Endothelial function (EnF) is impaired in patients with diabetes mellitus (DM) due in large part to an increase in oxidative stress. Haptoglobin (Hp) is a potent antioxidant protein which is encoded by two different alleles (1 and 2) with the Hp 1 protein being a superior antioxidant to the Hp 2 protein. We hypothesized that DM individuals with the Hp 2-2 genotype would have greater endothelial dysfunction as compared to DM individuals with the Hp 1-1 genotype. We studied EnF in 16 Hp 2-2, 14 Hp 1-1 DM individuals and 14 healthy subjects. DM patients' groups were matched in terms of age, cardiovascular risk factors and metabolic characteristics. EnF was assessed using post-ischemic reactive hyperemia and strain gauge plethysmography and expressed either as the maximal flow after the ischemic period or as the area under the flow-time curve (AUC). We showed that EnF indices, AUC and maximal flow, were also higher in the healthy and Hp 1-1 groups compared with Hp 2-2 genotype group (615 +/- 60 and 600 +/- 40 vs. 450 +/- 50 ml dl(-1), 29 +/- 2.6 and 25 +/- 3 vs. 14 +/- 1.8 ml min(-1) dl(-1), P < 0.003 and P < 0.05, for AUC and maximal flow, one-way ANOVA, respectively). We concluded that Hp 2-2 diabetic patients had a worse EnF than controls and Hp 1-1 diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347351     DOI: 10.1007/s00421-009-1048-z

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  25 in total

1.  Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: antioxidant role of haptoglobin.

Authors:  Y I Miller; S M Altamentova; N Shaklai
Journal:  Biochemistry       Date:  1997-10-07       Impact factor: 3.162

2.  Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.

Authors:  Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

3.  Structure-function analysis of the antioxidant properties of haptoglobin.

Authors:  M Melamed-Frank; O Lache; B I Enav; T Szafranek; N S Levy; R M Ricklis; A P Levy
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

4.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

5.  Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.

Authors:  Mahmoud Suleiman; Doron Aronson; Rabea Asleh; Michael R Kapeliovich; Ariel Roguin; Simcha R Meisel; Michael Shochat; Abeer Sulieman; Shimon A Reisner; Walter Markiewicz; Haim Hammerman; Rachel Lotan; Nina S Levy; Andrew P Levy
Journal:  Diabetes       Date:  2005-09       Impact factor: 9.461

Review 6.  Diabetes and cardiovascular disease.

Authors:  B V Howard; M F Magee
Journal:  Curr Atheroscler Rep       Date:  2000-11       Impact factor: 5.113

Review 7.  The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors.

Authors:  A L Peters; D L Schriger
Journal:  Am J Med       Date:  1998-07-06       Impact factor: 4.965

Review 8.  New methods to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric oxide-dependent and -independent vasodilation.

Authors:  Yukihito Higashi; Masao Yoshizumi
Journal:  J Pharmacol Sci       Date:  2003-12       Impact factor: 3.337

9.  The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients.

Authors:  P R Casino; C M Kilcoyne; A A Quyyumi; J M Hoeg; J A Panza
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

10.  Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL.

Authors:  Vladimir V Bamm; Vladimir A Tsemakhovich; Matityahu Shaklai; Nurith Shaklai
Journal:  Biochemistry       Date:  2004-04-06       Impact factor: 3.162

View more
  5 in total

Review 1.  The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.

Authors:  Tim Vanuytsel; Séverine Vermeire; Isabelle Cleynen
Journal:  Tissue Barriers       Date:  2013-12-10

2.  Epistasis between the haptoglobin common variant and α+thalassemia influences risk of severe malaria in Kenyan children.

Authors:  Sarah H Atkinson; Sophie M Uyoga; Emily Nyatichi; Alex W Macharia; Gideon Nyutu; Carolyne Ndila; Dominic P Kwiatkowski; Kirk A Rockett; Thomas N Williams
Journal:  Blood       Date:  2014-01-29       Impact factor: 22.113

3.  Assessment of haptoglobin alleles in autism spectrum disorders.

Authors:  Francesca Anna Cupaioli; Ettore Mosca; Chiara Magri; Massimo Gennarelli; Marco Moscatelli; Maria Elisabetta Raggi; Martina Landini; Nadia Galluccio; Laura Villa; Arianna Bonfanti; Alessandra Renieri; Chiara Fallerini; Alessandra Minelli; Anna Marabotti; Luciano Milanesi; Alessio Fasano; Alessandra Mezzelani
Journal:  Sci Rep       Date:  2020-05-08       Impact factor: 4.379

4.  Evaluation of haptoglobin genotypes in patients with metabolic syndrome: A preliminary report.

Authors:  Alireza Nakhaee; Mohammad Hashemi; Alireza Rezaeifar; Mahmoud Ali Kaykhaei
Journal:  ARYA Atheroscler       Date:  2015-05

5.  Haptoglobin 2-2 Phenotype Is Associated With Increased Acute Kidney Injury After Elective Cardiac Surgery in Patients With Diabetes Mellitus.

Authors:  Chenzhuo Feng; Bhiken I Naik; Wenjun Xin; Jennie Z Ma; David C Scalzo; Swapna Thammishetti; Robert H Thiele; Zhiyi Zuo; Jacob Raphael
Journal:  J Am Heart Assoc       Date:  2017-10-05       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.